F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine

February 19, 2026

The FDA has reversed its earlier decision and will now review Moderna's application for its new mRNA flu vaccine. This decision follows further discussions and a resolution of a public dispute regarding the vaccine's efficacy in older adults, with potential availability targeted for the 2026-27 flu season.

F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine

Key Highlights

The FDA will review Moderna's application for its mRNA flu vaccine.
The application was initially blocked due to concerns over a clinical trial.
Moderna's flu shot aims to be the first mRNA flu vaccine.
The vaccine could be available for the 2026-27 flu season.
The review follows a resolution of a dispute between Moderna and the FDA.

Drugs (Pharmaceuticals)Vaccination and Immunization Regulation and Deregulation of Industry Influenza RNA (Ribonucleic Acid)Medicine and Health Coronavirus (2019-nCoV)Food and Drug Administration Moderna Inc Health and Human Services Department Kennedy, Robert F Jr 2 Health

Sources

This quick summary is automatically generated using AI based on reports from multiple news sources. The content has not been reviewed or verified by humans. For complete details, accuracy, and context, please refer to the original published articles.

F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine

Key Highlights

Sources

Related Stories

Ships Avoid Hormuz As Iran Media Says It's Practically Shut

Three-time ex-MLA expelled from BJD hours after challenging Rajya Sabha picks

Opposition raises SIR concerns in Gujarat Assembly debate; Speaker allows limited discussion on exercise